News Center | Xian Janssen Pharmaceutical Ltd.

Company Announcement

Previous Pause Next

Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review

Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review

Highlights progress and commitment to deliver breakthrough medicines to meet the needs of patients around the worldPlans to maximize potential of leading brands by filing more than 40

[Media Report] Serving In the Name of Progress

[Media Report] Serving In the Name of Progress

In an interview with China Daily, Joaquin Duato, Executive Vice-President and Worldwide Chairman of Pharmaceuticals at Johnson&Johnson

China Food and Drug Administration approves IMBRUVICA® (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs

China Food and Drug Administration approves IMBRUVICA® (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs

[Beijing], [30 August, 2017] – Xian Janssen Pharmaceutical Ltd.

1

2

3

Follow us on WeChat

Corporate News

2019/05/16

Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review

2018/03/27

Janssen joins partnership in China to provide access to SIRTURO® (bedaquiline) for the treatment of multidrug-resistant tuberculosis (MDR-TB)

2018/01/23

IMBRUVICA and REMICADE included on the Zhejiang Province Reimbursement List for Drugs Treating Major Illnesses

2017/11/13

XIAN JANSSEN LAUNCHES EARLY IMBRUVICA® (IBRUTINIB)

2017/09/25

【ChinaDaily】Serving in the name of progress

2017/09/21

Xian Janssen and Shaanxi Province Forestry Department Announce a New Phase of Collaboration to Protect Giant Pandas

2017/07/19

Xian Janssen: VELCADE® and ZYTIGA® Included on the NRDL 2017

2017/05/19

Johnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical Business Review Meeting